Addressing Drug Resistance in Cancer: A Team Medicine Approach

Drug resistance remains one of the major impediments to treating cancer. Although many patients respond well initially, resistance to therapy typically ensues. Several confounding factors appear to contribute to this challenge. Here, we first discuss some of the challenges associated with drug resis...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2022-09, Vol.11 (19), p.5701
Main Authors: Kulkarni, Prakash, Mohanty, Atish, Bhattacharya, Supriyo, Singhal, Sharad, Guo, Linlin, Ramisetty, Sravani, Mirzapoiazova, Tamara, Mambetsariev, Bolot, Mittan, Sandeep, Malhotra, Jyoti, Gupta, Naveen, Kim, Pauline, Babikian, Razmig, Rajurkar, Swapnil, Subbiah, Shanmuga, Tan, Tingting, Nguyen, Danny, Merla, Amartej, Kollimuttathuillam, Sudarsan V, Phillips, Tanyanika, Baik, Peter, Tan, Bradford, Vashi, Pankaj, Shrestha, Sagun, Leach, Benjamin, Garg, Ruchi, Rich, Patricia L, Stewart, F Marc, Pisick, Evan, Salgia, Ravi
Format: Article
Language:English
Subjects:
Biology
Cancer therapies
Clinical medicine
Drug dosages
Drug resistance
Epigenetics
Gene expression
Genetic disorders
Genomes
Genotype & phenotype
Medicine
Metastasis
Mutation
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Drug resistance remains one of the major impediments to treating cancer. Although many patients respond well initially, resistance to therapy typically ensues. Several confounding factors appear to contribute to this challenge. Here, we first discuss some of the challenges associated with drug resistance. We then discuss how a 'Team Medicine' approach, involving an interdisciplinary team of basic scientists working together with clinicians, has uncovered new therapeutic strategies. These strategies, referred to as intermittent or 'adaptive' therapy, which are based on eco-evolutionary principles, have met with remarkable success in potentially precluding or delaying the emergence of drug resistance in several cancers. Incorporating such treatment strategies into clinical protocols could potentially enhance the precision of delivering personalized medicine to patients. Furthermore, reaching out to patients in the network of hospitals affiliated with leading academic centers could help them benefit from such innovative treatment options. Finally, lowering the dose of the drug and its frequency (because of intermittent rather than continuous therapy) can also have a significant impact on lowering the toxicity and undesirable side effects of the drugs while lowering the financial burden carried by the patient and insurance providers.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm11195701